Upstream Bio, Stock Price Prediction
| UPB Stock | 21.26 2.30 12.13% |
Oversold Vs Overbought
0
Oversold | Overbought |
Using Upstream Bio, hype-based prediction, you can estimate the value of Upstream Bio, from the perspective of Upstream Bio, response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Upstream Bio, to buy its stock at a price that has no basis in reality. In that case, they are not buying Upstream because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Upstream Bio, after-hype prediction price | USD 20.53 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Upstream |
Upstream Bio, After-Hype Price Prediction Density Analysis
As far as predicting the price of Upstream Bio, at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Upstream Bio, or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Upstream Bio,, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Upstream Bio, Estimiated After-Hype Price Volatility
In the context of predicting Upstream Bio,'s stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Upstream Bio,'s historical news coverage. Upstream Bio,'s after-hype downside and upside margins for the prediction period are 13.37 and 27.69, respectively. We have considered Upstream Bio,'s daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Upstream Bio, is somewhat reliable at this time. Analysis and calculation of next after-hype price of Upstream Bio, is based on 3 months time horizon.
Upstream Bio, Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Upstream Bio, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Upstream Bio, backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Upstream Bio,, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.86 | 7.16 | 0.73 | 0.26 | 6 Events / Month | 6 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
21.26 | 20.53 | 3.43 |
|
Upstream Bio, Hype Timeline
On the 28th of November Upstream Bio, is traded for 21.26. The entity has historical hype elasticity of -0.73, and average elasticity to hype of competition of -0.26. Upstream is projected to decline in value after the next headline, with the price expected to drop to 20.53. The average volatility of media hype impact on the company price is over 100%. The price depreciation on the next news is expected to be -3.43%, whereas the daily expected return is at this time at 0.86%. The volatility of related hype on Upstream Bio, is about 2351.82%, with the expected price after the next announcement by competition of 21.00. The company had not issued any dividends in recent years. Considering the 90-day investment horizon the next projected press release will be in about 6 days. Check out Upstream Bio, Basic Forecasting Models to cross-verify your projections.Upstream Bio, Related Hype Analysis
Having access to credible news sources related to Upstream Bio,'s direct competition is more important than ever and may enhance your ability to predict Upstream Bio,'s future price movements. Getting to know how Upstream Bio,'s peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Upstream Bio, may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| VIGL | Vigil Neuroscience | 0.01 | 5 per month | 0.00 | (0.12) | 6.33 | (7.22) | 37.50 | |
| VINC | Vincerx Pharma | (0.01) | 4 per month | 0.00 | (0.23) | 5.71 | (7.32) | 47.76 | |
| VIRX | Viracta Therapeutics | (0.01) | 4 per month | 0.00 | (0.13) | 6.67 | (8.00) | 26.79 | |
| VNDA | Vanda Pharmaceuticals | 0.01 | 9 per month | 0.00 | (0.05) | 4.22 | (3.67) | 14.93 | |
| KTTAW | Pasithea Therapeutics Corp | (0.02) | 4 per month | 16.74 | 0.17 | 61.29 | (31.89) | 141.61 | |
| VRCA | Verrica Pharmaceuticals | (0.09) | 9 per month | 0.00 | (0.07) | 12.12 | (12.50) | 74.69 | |
| VRNA | Verona Pharma PLC | (2.07) | 11 per month | 1.79 | 0.17 | 7.31 | (3.34) | 14.37 | |
| VSTM | Verastem | (0.50) | 10 per month | 4.54 | 0.17 | 11.28 | (5.69) | 31.27 | |
| VTGN | VistaGen Therapeutics | (0.06) | 10 per month | 0.00 | (0.21) | 3.46 | (3.82) | 10.58 |
Upstream Bio, Additional Predictive Modules
Most predictive techniques to examine Upstream price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Upstream using various technical indicators. When you analyze Upstream charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Upstream Bio, Predictive Indicators
The successful prediction of Upstream Bio, stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Upstream Bio,, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Upstream Bio, based on analysis of Upstream Bio, hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Upstream Bio,'s market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Upstream Bio,'s related companies.
Story Coverage note for Upstream Bio,
The number of cover stories for Upstream Bio, depends on current market conditions and Upstream Bio,'s risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Upstream Bio, is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Upstream Bio,'s long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Complementary Tools for Upstream Stock analysis
When running Upstream Bio,'s price analysis, check to measure Upstream Bio,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Upstream Bio, is operating at the current time. Most of Upstream Bio,'s value examination focuses on studying past and present price action to predict the probability of Upstream Bio,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Upstream Bio,'s price. Additionally, you may evaluate how the addition of Upstream Bio, to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |